Iris melanocytoma: Clinical features and natural course in 47 cases
Purpose
To describe the clinical features, natural course, management and histopathologic features of iris melanocytoma.
Design
Single-center retrospective case series.
Methods
patient population: Forty-seven consecutive patients (47 eyes) with iris melanocytoma. intervention procedure: Data regarding patient and tumor features were analyzed for their impact on the main outcome measures using univariate and multivariate regression models. Kaplan-Meier estimates were used to analyze the main outcomes as a function of time. main outcome measures: Increased intraocular pressure (IOP), tumor seeding, and tumor growth.
Results
Associated findings at initial presentation included iris stromal seeds in 20 patients (43%), and anterior chamber angle seeds in 12 (26%). Intrinsic vascularization and sector cataract were not seen in any eyes. The management at presentation included observation in 39 patients (83%), tumor removal by sector iridectomy/iridocyclectomy in 7 (15%), and enucleation for blind painful eye with secondary increased IOP in 1 (2%). The diagnosis was confirmed by histopathologic examination in 11 patients (23%). The mean follow-up was 58 months. Using Kaplan-Meier estimates, clinical evidence of growth was observed in 23% at 5 years, 48% at 10 years, and 74% at 15 years. New tumor seeds developed in 34% at 5 years, 63% at 10 years, and 75% at 15 years. Increased IOP was observed in 11% at 5 years, 11% at 10 years, and 55% at 15 years.
Conclusions
Iris melanocytoma represented only 3% of all iris nevi. Related iris stromal and anterior chamber angle seeds were common, and secondary glaucoma occurred in 11% at 5 years. Growth was observed in 23% at 5 years but no malignant transformation was found.
To access this article, please choose from the options below
Support provided by the International Award of Merit in Retina Research, Houston, Texas (J.A.S.), Rosenthal Award of the Macula Society (C.L.S.), Macula Foundation, New York, New York (C.L.S.), the Noel T. and Sara L. Simmonds Endowment for Ophthalmic Pathology, Wills Eye Hospital (R.C.E., Jr.) and the Eye Tumor Research Foundation, Philadelphia, Pennsylvania (C.L.S., J.A.S.).
PII: S0002-9394(04)01246-2
doi:10.1016/j.ajo.2004.10.008
© 2005 Elsevier Inc. All rights reserved.
